LONDON--Cyprotex PLC (CRX.LN), the preclinical ADME-Tox services company, Tuesday announced a collaborative research agreement between its wholly owned subsidiary Apredica LLC and Pfizer Inc. (PFE).

MAIN FACTS:

-No financial details have been disclosed

-The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved

-The collaboration is a research-based project which the parties aim to evaluate, further develop, and improve several of Cyprotex's proprietary offerings in the area of predictive toxicology

-Shares closed Monday at 4.25 pence valuing the company at GBP10 million.

Write to Jana Weigand at jana.weigand@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Cyprotex (LSE:CRX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Cyprotex Charts.
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Cyprotex Charts.